

# AJKD


VOL 26, NO 6, DECEMBER 1995

FUDGER MEDICAL LIBRARY  
THE TORONTO HOSPITAL  
GENERAL DIVISION

\*\*\* CURRENT ISSUE \*\*\*

AEAZ

American Journal of Kidney Diseases



3065542

**NKF** The Official Journal of the  
**National Kidney Foundation**

W. B. Saunders Company • A Division of Harcourt Brace & Company

Copied from Volume from  
**CANOPY**  
Further reproduction prohibited

# American Journal of Kidney Diseases

**NKF** The Official Journal of the  
**National Kidney Foundation**

## Editor-in-Chief

Saulo Klahr, MD

## Consulting Editors

Robert G. Luke, MD

George A. Porter, MD

## Assistant Editors

James A. Delmez, MD

Kevin J. Martin, MD

George F. Schreiner, MD

## Associate Editors

Adrian I. Katz, MD

Bryan D. Myers, MD

Giuseppe Remuzzi, MD

Norman J. Siegel, MD

## Editorial Board

Hannah E. Abboud

Paul A. Abraham

Lawrence Agodoa

Robert Jay Alpern

Charles E. Alpers

Sharon Anderson

Raymond Ardaillou

George R. Aronoff

Robert C. Atkins

Ellis D. Avner

Morrell M. Avram

James E. Balow

Daniel C. Batlle

William M. Bennett

Jonas Bergstrom

Tomas Berl

Christopher R. Blagg

Warren Kline Bolton

Vittorio Bonomini

Wayne A. Border

Peter C. Brazy

Daniel Brennan

J. D. Briggs

J. Stewart Cameron

Giulio A. Cinotti

Frederic L. Coe

Robert B. Colvin

John J. Curtis

Giuseppe D'Amico

Thomas O. Daniel

Connie L. Davis

Marc E. De Broe

Tilman B. Drüeke

Thomas D. DuBose, Jr

Lance D. Dworkin

Garabed Eknayan

Murray Epstein

Ronald J. Falk

Agnes Fogo

Eli A. Friedman

Patricia A. Gabow

John H. Galla

Kenneth D. Gardner

Robert Gaston

Richard J. Glasscock

Stanley Goldfarb

M. L. Halperin

L. Lee Hamm

Lee A. Hebert

Lee W. Henderson

William L. Henrich

Alan R. Hull

Iekuni Ichikawa

Bertram L. Kasiske

William F. Keane

Carl M. Kjellstrand

Donald E. Kohan

Stephen M. Korbet

Rajiv Kumar

Kiyoshi Kurokawa

Neil A. Kurtzman

Andrew S. Levey

Nathan W. Levin

Edmund J. Lewis

Victoria S. Lim

Marshall D. Lindheimer

Friedrich C. Luft

Manuel Martinez-Maldonado

Shaul G. Massry

S. Michael Mauer

William M. McClellan

William Evans Mitch

Bruce A. Molitoris

Aubrey R. Morrison

Cynthia C. Nast

Karl A. Nath

Karl D. Nolph

Klaus Olgaard

Tom F. Parker, III

D. Keith Peters

Beth Piraino

Venkateswara Rao

Helmut G. Rennke

Martin I. Resnick

Richard A. Rettig

Eberhard Ritz

David John Salant

Nestor Schor

Robert W. Schrier

Steve J. Schwab

Sudhir V. Shah

Richard A. Sherman

Donald James Sherrard

Eduardo Slatopolsky

Gary E. Striker

C. Craig Tisher

Fernando Valderrabano

John Walls

David G. Warnock

Roger Charles Wiggins

James F. Winchester

David Windus

Marsha Wolfson

## CONTENTS

### IN-DEPTH REVIEW

Advanced Glycosylation End Products in Diabetic Renal and Vascular Disease

*Richard Bucala and Helen Vlassara* 875

### ORIGINAL INVESTIGATIONS

Status of Patients Who Underwent Uninephrectomy in Adulthood More Than 20 Years Ago

*Akira Ohishi, Hiromichi Suzuki, Hidetomo Nakamoto, Hiroshige Katsumata,*

*Kouichi Hayashi, Munekazu Ryuzaki, Kazuhiro Kumagai, Tomohiro Furukawa,*

*Atsuhiko Ichihara, Takao Saruta, Fuyuhiko Higashi, and Ken Marumo* 889

Acquired Oligonephropathy and Diabetic Nephropathy ..... *Flemming S. Nielsen,*

*Mari-Anne Gall, and Hans-Henrik Parving* 898

The Urine Protein to Creatinine Ratio as a Predictor of 24-Hour Urine Protein Excretion in

Type 1 Diabetic Patients With Nephropathy ..... *Roger A. Rodby, Richard D. Rohde,*

*Zeev Sharon, Marc A. Pohl, Raymond P. Bain,*

*and Edmund J. Lewis, for the Collaborative Study Group* 904

Bicarbonate Dialysate for Continuous Renal Replacement Therapy in Intensive Care Unit

Patients With Acute Renal Failure ..... *Martine Leblanc, Luz Moreno,*

*Orlandus P. Robinson, Mihaly Tapolyai, and Emil P. Paganini* 910

Pharmacologic Profile of Diaspirin Cross-Linked Hemoglobin in Hemodialysis Patients

*Suzanne K. Swan, Charles E. Halstenson, Allan J. Collins, Wayne A. Colburn,*

*John Blue, and Robert J. Przybelski* 918

In Vitro Effects of Bicarbonate- Versus Lactate-Buffered Continuous Ambulatory Peritoneal

Dialysis Fluids on Peritoneal Macrophage Function .... *Frank-Peter Fischer, Uwe Schenk,*

*Thomas Kiefer, Eugen Hübel, Stefan Thomas, Hippokrates Yatzidis, Thomas Mettang,*

*and Ulrich Kuhlmann* 924

Proximal Tubular Cell Synthesis and Secretion of Endothelin-1 on Challenge With Albumin

and Other Proteins ..... *Carla Zoja, Marina Morigi, Marina Figliuzzi,*

*Isabella Bruzzi, Simon Oldroyd, Ariela Benigni, Pierre Ronco, and Giuseppe Remuzzi* 934

Cilazapril Delays Progression of Hypertension and Uremia in Rat Polycystic Kidney Disease

*Malcolm R. Ogborn, Sanjay Sareen, and Gilles Pinette* 942

### Cover Legend:

Fig 2. Electron micrograph of glomerular capillary loops in a patient with Fabry's disease. Lamellar and myelinoid inclusions are accumulated in visceral epithelial cell cytoplasm. (Original magnification  $\times 1,500$ .) See Fukushima et al, p. 952.

## CASE REPORTS

- Interstitial Nephritis in Sarcoidosis: Simultaneous Multiorgan Involvement  
*Josep M. Cruzado, Rafael Poveda, Joan Mañá, Luis Carreras, Marta Carrera,  
Josep M. Grinyó, and Jeroni Alsina* 947
- A Female Heterozygous Patient With Fabry's Disease With Renal Accumulation of  
Trihexosylceramide Detected With a Monoclonal Antibody ..... *Masaki Fukushima,  
Yoshinori Tsuchiyama, Tatsuaki Nakato, Toru Yokoi, Hiroshi Ikeda, Soichiro Yoshida,  
Toru Kusumoto, Kohji Itoh, and Hitoshi Sakuraba* 952
- Progression to Calcific Mitral Stenosis in End-Stage Renal Disease ..... *Ivan A. D'Cruz  
and Ernest C. Madu* 956
- Metastatic Renal Carcinoma in a Pediatric Recipient of an Adult Cadaveric Donor Kidney  
*Danny Lotan and Joseph Laufer* 960

## EDITORIAL OPINION

- A Proposed Glossary for Dialysis Kinetics ..... *Joel D. Kopple, Michael R. Jones,  
Prakash R. Keshaviah, Jonas Bergström, Robert M. Lindsay, John Moran, Karl D. Nolph,  
and Brendan P. Teehan* 963

## PHYSIOLOGY AND CELL BIOLOGY UPDATE

- Chemokines and Renal Disease ..... *Ulrich O. Wenzel and Hanna E. Abboud* 982

## NATIONAL KIDNEY FOUNDATION POSITION PAPER

- Proposed Health Care Financing Administration Guidelines for Reimbursement of Enteral  
and Parenteral Nutrition .... *Joel D. Kopple, Charles J. Foulks, Beth Piraino, Judith A. Beto,  
and Jordy Goldstein* 995

- CURRENT **KUHN**NOTATIONS ..... *Gary E. Striker* 998

- CORRESPONDENCE ..... 1000

- BOOKS RECEIVED ..... 1002

- ACKNOWLEDGMENTS ..... 1003

- INDEX ..... 1006

- ANNOUNCEMENTS ..... xvi

# Bicarbonate Dialysate for Continuous Renal Replacement Therapy in Intensive Care Unit Patients With Acute Renal Failure

Martine Leblanc, MD, Luz Moreno, MD, Orlandus P. Robinson, CHT, Mihaly Tapolyai, MD, and Emil P. Paganini, MD

● Lactate-buffered peritoneal solution traditionally has been used as dialysate for continuous renal replacement therapy (CRRT) in the United States because no bicarbonate solution is commercially available. Since 1994, the Cleveland Clinic Foundation Dialysis Unit has prepared a bicarbonate solution (sodium  $144 \pm 3$  mEq/L,  $\text{HCO}_3^-$   $37 \pm 2$  mEq/L, potassium 3 or 4 mEq/L, calcium  $3.0 \pm 0.3$  mEq/L, and magnesium  $1.4 \pm 0.3$  mg/dL) replicating the dialysate for chronic intermittent hemodialysis. No solute precipitation, as calcium or magnesium salts, were observed, and several cultures of the solution, performed at various time periods, remained negative. Fifty critically ill acute renal failure patients have been treated with bicarbonate-CRRT. All patients were in multiple organ failure and required mechanical ventilation; 37 were receiving vasopressors. Forty-four continuous venovenous hemodialysis sessions and eight continuous arteriovenous hemodialysis sessions were performed with a mean duration of  $7.8 \pm 6.1$  days. The mean inflow dialysate rate was  $1,249 \pm 225$  mL/hr and the mean outflow rate (dialysate plus ultrafiltration) was  $1,399 \pm 237$  mL/hr; the inflow rate was constantly kept lower or equal to the outflow rate to avoid an enhanced potential for backfiltration. No related fever spikes or sepsis episodes were noted. The metabolic control achieved during bicarbonate-CRRT was good, with the following mean ( $\pm$ SD) daily values: blood urea nitrogen  $70.3 \pm 29.0$  mg/dL, creatinine  $3.6 \pm 1.3$  mg/dL, sodium  $135.7 \pm 3.7$  mEq/L, potassium  $4.6 \pm 0.5$  mEq/L, chloride  $99.9 \pm 4.6$  mEq/L, carbon dioxide content  $21.4 \pm 3.4$  mEq/L, calculated anion gap  $14.4 \pm 4.8$  mEq/L, arterial pH  $7.39 \pm 0.05$ , arterial  $\text{PCO}_2$   $36.6 \pm 5.4$  mm Hg, total calcium  $8.7 \pm 0.9$  mg/dL (corrected for albumin 9.6), phosphorus  $4.2 \pm 1.4$  mg/dL, and magnesium  $2.06 \pm 0.26$  mg/dL. A subgroup of 13 patients was treated with two dialysate types, lactate-based solution (Dianeal 1.5%; Baxter Healthcare Corporation, Deerfield, IL) for  $3.2 \pm 1.5$  days and bicarbonate solution for  $7.4 \pm 1.6$  days, and the obtained metabolic control under both types of dialysate was compared. Mean values  $\pm$  SD (with probability values) obtained with lactate dialysate versus bicarbonate dialysate were as follows: blood urea nitrogen  $77.6 \pm 34.4$  mg/dL versus  $71.0 \pm 20.8$  mg/dL ( $P = \text{NS}$ ), creatinine  $4.1 \pm 0.9$  mg/dL versus  $3.3 \pm 1.6$  mg/dL ( $P = \text{NS}$ ), sodium  $132.8 \pm 4.8$  mEq/L versus  $135.6 \pm 2.9$  mEq/L ( $P = 0.04$ ), chloride  $95.8 \pm 5.4$  mEq/L versus  $98.5 \pm 4.2$  mEq/L ( $P = \text{NS}$ ), carbon dioxide content  $17.8 \pm 3.1$  mEq/L versus  $21.8 \pm 3.4$  mEq/L ( $P = 0.002$ ), calculated anion gap  $19.3 \pm 4.4$  mEq/L versus  $15.2 \pm 3.8$  mEq/L ( $P = 0.008$ ), arterial pH  $7.36 \pm 0.07$  versus  $7.40 \pm 0.06$  ( $P = \text{NS}$ ), arterial  $\text{PCO}_2$   $32.1 \pm 5.3$  mm Hg versus  $37.8 \pm 3.8$  mm Hg ( $P = 0.01$ ), total calcium  $8.3 \pm 1.1$  mg/dL versus  $8.8 \pm 1.0$  mg/dL ( $P = \text{NS}$ ), phosphorus  $4.7 \pm 1.3$  mg/dL versus  $3.8 \pm 1.4$  mg/dL ( $P = \text{NS}$ ), magnesium  $1.95 \pm 0.14$  mg/dL versus  $2.04 \pm 0.34$  mg/dL ( $P = \text{NS}$ ), and glucose  $200.5 \pm 80.4$  mg/dL versus  $146.7 \pm 40.4$  mg/dL ( $P = 0.04$ ). The bicarbonate solution is simple to prepare and is cost-effective. In our experience, its use as dialysate for CRRT is safe, free of complications, and provides an excellent metabolic control.

© 1995 by the National Kidney Foundation, Inc.

**INDEX WORDS:** Continuous renal replacement therapy; bicarbonate dialysate; lactate-based dialysate; acid-base status; acute renal failure.

ONE OF THE major aims of renal replacement therapy in patients with chronic or acute renal failure (ARF), besides the control of azotemia and electrolyte disturbances, is the correction of the associated metabolic acidosis. It is known that metabolic acidosis can lead to several detrimental effects: an increase in protein turn-

over with consequent muscle protein degradation and enhanced catabolism,<sup>1-3</sup> progression of bone lesions through dissolution of mineral buffers,<sup>4</sup> and a depression of myocardial contractility consequent to a lower response to circulating catecholamines.<sup>5,6</sup>

It is now well accepted that acetate dialysis, particularly high-efficiency acetate dialysis, can lead to vascular instability and hypoxia.<sup>7</sup> In critically ill patients, bicarbonate hemodialysis has been associated with less intradialytic hypotension than acetate hemodialysis.<sup>8</sup> Despite a hemodynamic advantage, some technical problems relating to on-line bicarbonate dialysate preparation still remain: bicarbonate instability with the potential for calcium and magnesium salt precipitation over time and the risk of bacteremia and

*From the Department of Nephrology/Hypertension, The Cleveland Clinic Foundation, Cleveland, OH.*

*Received April 13, 1995; accepted in revised form July 24, 1995.*

*Address reprint requests to Emil P. Paganini, MD, Section of Dialysis and Extracorporeal Therapy, Department of Nephrology/Hypertension, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195.*

© 1995 by the National Kidney Foundation, Inc.  
0272-6386/95/2606-0005\$3.00/0

endotoxemia consequent to a more rapid bacterial growth in the liquid bicarbonate concentrate.<sup>9,10</sup>

Continuous renal replacement therapies (CRRTs) are well recognized as advantageous alternatives to intermittent hemodialysis for intensive care unit (ICU) ARF patients. To our knowledge, at the present time, most centers in the United States performing CRRT are using lactate-buffered peritoneal solutions as dialysate and also, in certain cases, as replacement fluid. Sterile bicarbonate solution is available for replacement fluid for continuous hemofiltration, but, since it is very expensive, it is generally not used for dialysate for other forms of CRRT.

In the past, there has been concern that the infusion of large amounts of D,L-lactate from Ringer's solution or peritoneal dialysis solution could lead to increased catabolism and cerebral dysfunction.<sup>9,11</sup> To date, only one study has been published on the use of bicarbonate-based dialysate for CRRT. It included five pediatric patients treated by continuous arteriovenous hemodialysis (CAVHD), and the results suggested an improvement of the metabolic acidosis with bicarbonate dialysate compared with lactate or acetate dialysates.<sup>12</sup>

Since 1994, the Cleveland Clinic Foundation Dialysis Unit has prepared a bicarbonate-based solution as an alternative to the usual lactate-buffered solution used as dialysate for CRRT. This new solution is now considered the standard dialysate for ICU ARF patients treated by CRRT at this institution. Our present objective is to report the preparation procedure of the bicarbonate dialysate and the favorable experience with its use in a group of 50 ICU patients.

## MATERIALS AND METHODS

### *Patients*

Since 1994, the prepared bicarbonate solution has been used as dialysate for 50 ICU ARF patients treated by CRRT. The following patient data were recorded: demographics; Acute Physiology Age Chronic Health Evaluation (APACHE II) score at the time of admission to the ICU; hemodynamic parameters at initiation of CRRT; ventilatory, pressor, and nutritional support during CRRT; type and duration of CRRT; inflow dialysate rate and outflow (dialysate plus ultrafiltration) rate; and blood flow rate when on continuous venovenous hemodialysis (CVVHD). Daily metabolic parameters (from routine early morning laboratory examinations), including blood urea nitrogen (BUN), creatinine, sodium, po-

tassium, chloride, carbon dioxide content (bicarbonate and dissolved carbon dioxide), calculated anion gap, arterial pH, arterial PCO<sub>2</sub>, total calcium, albumin, phosphorus, magnesium, glucose, and arterial lactic acid, when available, obtained during the entire period of CRRT with the bicarbonate dialysate, were recorded.

A subgroup of 13 patients treated by CRRT with lactate dialysate, generally followed by bicarbonate dialysate, served as its own control to compare the metabolic control achieved. The data from this subgroup were analyzed separately. Daily metabolic parameters and duration of CRRT under each type of dialysate were recorded.

Blood was obtained from indwelling arterial catheters. Serum chemistries were analyzed by usual laboratory methods (Beckman Synchron CX-3, Brea, CA); blood gases were processed by an automated blood gas analyzer (model 288; Ciba-Corning, Medfield, MA). Samples for arterial blood L-lactate were collected and stored on ice and were analyzed using an enzymatic method (model 2300; WSI, Antioch, OH).

### *Dialysate Solution Preparation*


The solution was prepared by the dialysis technicians using volumetric single-pass dialysis machines (Althin-1000; Althin CD Medical Inc, Miami, FL). These single-patient proportioning dialysis machines use two concentrates (acid and bicarbonate), and mix heated water (treated by reverse osmosis in our dialysis unit) with the dialysate concentrate to create a solution with the correct ionic composition and physiologic temperature. The conductivity was set to correspond to a sodium concentration of 140 mEq/L and the chosen temperature was 37°C. The obtained dialysate was then inflowed at 500 to 900 mL/min into the dialysate compartment of a high-flux, hollow-fiber, polysulfone membrane dialyzer (F-80; Fresenius AG, Bad Homburg, Germany) and allowed to transfer by backfiltration into the dialyzer blood compartment, from which it was drained into sterile 12- to 15-L plastic bags (Cycler Drainage Set; Baxter Healthcare Corporation, Deerfield, IL). The nondraining line of the dialyzer blood compartment was used for degassing and for solution sampling, while the unused dialysate port was clamped during the procedure. Figure 1 is a schematic representation of the procedure.

Filled plastic bags were sealed with plastic tie clamps after the procedure and kept at room temperature for a maximum of 72 hours. If not used within 72 hours, they were discarded. One hemofilter was used to prepare approximately 12 to 15 bags, each containing 12 to 15 L of dialysate solution. Two bags were hung on a large circular pole for use during CRRT. The solution so produced was a replication of the standard dialysate used during intermittent bicarbonate hemodialysis, and thus no further justification for its use was judged necessary.

### *Solute Concentrations in Dialysate*

Several aliquots of dialysate solution were sent for laboratory analysis. The mean solute concentrations obtained are shown in Table 1; those of the traditional lactate solution (Dianeal 1.5%, Baxter Healthcare Corporation) are also indicated for comparison.

Although the preparation procedure of the dialysate solution was sterile, the solution itself cannot be considered as a



**Fig 1.** Schematic representation of the preparation of the bicarbonate solution used as dialysate. Reverse osmosis-treated water (A) was mixed by proportioning dialysis machines with acid and bicarbonate concentrates (B). The dialysate so produced was then flowed into the dialysate compartment (C) and allowed to transfer by backfiltration into the dialyzer blood compartment, from which it was drained into sterile plastic bags (D).

sterile fluid. However, several cultures of dialysate samples taken every day for a period of 3 weeks did not show any microbial growth. Since the presence of endotoxins is possible,<sup>10</sup> this solution has not been used as replacement fluid, but only as dialysate. No solute precipitation (as calcium or magnesium salts) was observed within the time of use and in several bags observed over more than 2 weeks, but the presence of microprecipitation cannot be excluded.

### Techniques for Continuous Renal Replacement Therapy

Either continuous arteriovenous or venovenous hemodialysis sessions (44 CVVHD and eight CAVHD) were performed in this study. The hemofilters used in 46 sessions were hollow-fiber, polyacrylonitrile-membrane PAN-50 (Asahi, Asahi Medical Co LTD, Tokyo, Japan); in the six remaining sessions, hollow-fiber polysulfone-membrane F-4 (Fresenius AG) filters were used. For CVVHD, a blood pump (Baxter Healthcare Corporation) maintained the blood flow rate between 150 and 200 mL/min. Most sessions were performed without any anticoagulation; heparin in doses between 250 to 750 U/hr was administered in only 12 cases. The dialysate was infused into the appropriate dialysate compartment of the filter at the prescribed rate via volumetric infusion pumps (McGaw Accu Pro; American Edwards Laboratories, Irvine, CA); similar pumps also controlled the outflow (dialysate plus ultrafiltration) rate at the prescribed level, as previously described.<sup>13</sup> The inflow rate was always kept either lower or equal to the outflow rate to avoid a positive pressure favoring

backfiltration.<sup>14,15</sup> While backfiltration and backdiffusion can still occur when large-pore membrane filters are used, the bicarbonate solution is similarly used as dialysate in chronic dialysis patients and has not been associated with deleterious clinical effects.

### Statistics

Results are presented as mean values  $\pm$  SD. Data were analyzed with Student's paired *t*-test, and  $P < 0.05$  was considered significant.

### RESULTS

The 50 cases treated with the bicarbonate dialysate were critically ill patients from surgical and medical ICUs and presented ARF requiring dialytic support. Only two cases had a primary diagnosis of severe liver failure, and all were in multiple organ failure at initiation of CRRT. There were 33 men and 17 women with a mean age of  $59.9 \pm 16.6$  years old and a mean APACHE II score at ICU admission of  $19.6 \pm 5.4$ . At initiation of CRRT, 76% of patients were oligoanuric and mean hemodynamic parameters showed the following values: mean arterial blood pressure  $78 \pm 22$  mm Hg, heart rate  $101 \pm 14$  beats/min, and cardiac output and systemic vascular resistances (available for only 43 patients)  $7.4 \pm 3.9$  L/min and  $758 \pm 427$  dyne  $\cdot$  sec  $\cdot$  cm<sup>5</sup>, respectively. During CRRT, all patients were mechanically ventilated and 37 were receiving vaso-

**Table 1. Composition of the Bicarbonate Solution and Dianeal 1.5%**

	Dianeal 1.5%	Bicarbonate Solution
Sodium (mEq/L)	132	144 $\pm$ 3
Potassium (mEq/L)	3-4*	3.7 $\pm$ 0.2
Calcium (mEq/L)	3.5	3.0 $\pm$ 0.3
Magnesium (mEq/L)	1.5	1.4 $\pm$ 0.3
Chloride (mEq/L)	102	111 $\pm$ 3
Lactate (mEq/L)	35	—
Bicarbonate (mEq/L)	—	37 $\pm$ 2
Acetate (mEq/L)	—	2-4†
Glucose (anhydrous, mg/dL)	1300	205 $\pm$ 15

NOTE. Solute concentrations in the bicarbonate dialysate are the mean values  $\pm$  SD of seven aliquots sampled from different bags after preparation of the solution.

\* Potassium, as potassium chloride, was added to obtain a concentration of 3 or 4 mEq/L.

† Acetate was not measured, but was assumed to reach a concentration of 2 to 4 mEq/L, as reported for bicarbonate dialysate in chronic hemodialysis.

**Table 2. Metabolic Control of the 50 Patients During Continuous Renal-Replacement Therapy Using the Bicarbonate Dialysate**


BUN (mg/dL)	70.3 ± 29.0
Creatinine (mg/dL)	3.6 ± 1.3
Sodium (mEq/L)	135.7 ± 3.7
Potassium (mEq/L)	4.6 ± 0.5
Chloride (mEq/L)	99.9 ± 4.6
Carbon dioxide (HCO <sub>3</sub> + dissolved carbon dioxide; mEq/L)	21.4 ± 3.4
Calculated anion gap (mEq/L)	14.4 ± 4.8
Arterial pH	7.39 ± 0.05
Arterial PCO <sub>2</sub> (mm Hg)	36.6 ± 5.4
Total calcium (mg/dL)	8.7 ± 0.9
Albumin (g/L)	2.9 ± 0.7
Phosphorus (mg/dL)	4.2 ± 1.4
Magnesium (mg/dL)	2.06 ± 0.26
Glucose (mg/dL)	163.0 ± 73.6

NOTE: The results are expressed as mean values ± SD of the daily parameters obtained during the entire period of CRRT with the bicarbonate dialysate.

pressors for hemodynamic instability; 20 patients were receiving total parenteral nutrition, 14 patients were being tube fed, and 16 patients were receiving no nutritional support. The mean arterial lactic acid level within 24 hours before CRRT initiation, available for only 22 patients, was  $7.1 \pm 5.2$  mEq/L; subsequent monitoring of lactic acid concentrations was too erratic to draw any firm conclusion.

Forty-four CVVHD and eight CAVHD sessions using the bicarbonate solution as dialysate were performed over a mean of  $7.8 \pm 6.1$  days (range, 2 to 24 days). Two patients initially treated by CAVHD were changed over time to CVVHD for practical purposes. The mean inflow dialysate rate was  $1,249 \pm 225$  mL/hr and the mean outflow (dialysate plus ultrafiltration) rate was  $1,399 \pm 237$  mL/hr, leading to a mean hourly ultrafiltration rate of  $148 \pm 78$  mL. The metabolic control achieved for the 50 cases during bicarbonate-CRRT, expressed as the means of daily measurements, is shown in Table 2. Figure 2 presents the mean daily results of acid base status of the 50 patients prior to initiation, during the first days of treatment, and before discontinuation of CRRT.

A subgroup of 13 patients was treated with lactate-based dialysate (Dianeal 1.5%) for a mean period of  $3.2 \pm 1.5$  days and with bicarbonate dialysate for a mean period of  $7.4 \pm 1.6$  days,



**Fig 2.** Mean daily arterial PCO<sub>2</sub>, serum bicarbonate concentration (HCO<sub>3</sub>), and calculated anion gap (AG) before and during bicarbonate-CRRT for the 50 patients. Results after the broken horizontal axis were obtained the day preceding the end of CRRT. The units of measure are mm Hg for PCO<sub>2</sub> and mEq/L for HCO<sub>3</sub> and anion gap.

and the metabolic control achieved under both types of dialysate was compared. As shown in Table 3, the acid base balance was slightly improved during bicarbonate-CRRT, with a sig-

**Table 3. Comparison of the Metabolic Control With Lactate Dialysate and Bicarbonate Dialysate for the 13-Patient Subgroup**

	Dianeal 1.5%	Bicarbonate Solution	Probability Value
BUN (mg/dL)	77.6 ± 34.4	71.0 ± 20.8	NS
Creatinine (mg/dL)	4.1 ± 0.9	3.3 ± 1.6	NS
Sodium (mEq/L)	132.8 ± 4.8	135.6 ± 2.9	0.04
Chloride (mEq/L)	95.8 ± 5.4	98.5 ± 4.2	NS
Carbon dioxide (HCO <sub>3</sub> + dissolved carbon dioxide; mEq/L)	17.8 ± 3.1	21.8 ± 3.4	0.002
Calculated anion gap (mEq/L)	19.3 ± 4.4	15.2 ± 3.8	0.008
Arterial pH	7.36 ± 0.07	7.40 ± 0.06	NS
Arterial PCO <sub>2</sub> (mm Hg)	32.1 ± 5.3	37.8 ± 3.8	0.01
Total calcium (mg/dL)	8.3 ± 1.1	8.8 ± 1.0	NS
Phosphorus (mg/dL)	4.7 ± 1.3	3.8 ± 1.4	NS
Magnesium (mg/dL)	1.95 ± 0.14	2.04 ± 0.34	NS
Glucose (mg/dL)	200.5 ± 80.4	146.7 ± 40.4	0.04

NOTE: The results are expressed as mean values ± SD of daily values obtained during CRRT, with either lactate dialysate or bicarbonate dialysate.






Fig 3. Mean daily arterial PCO<sub>2</sub>, serum bicarbonate concentration (HCO<sub>3</sub>), and calculated anion gap (AG) at initiation and during 3 days of CRRT with each type of dialysate (lactate and bicarbonate) for the 13-patient subgroup. The units of measure are mm Hg for PCO<sub>2</sub> and mEq/L for HCO<sub>3</sub> and anion gap. (■) PCO<sub>2</sub> with bicarbonate; (□) PCO<sub>2</sub> with lactate; (●) HCO<sub>3</sub> with bicarbonate; (○) HCO<sub>3</sub> with lactate; (▲) AG with bicarbonate; (△) AG with lactate.

nificant increase in blood carbon dioxide (from 17.8 to 21.8 mEq/L) and a decrease in the calculated anion gap (from 19.3 to 15.2 mEq/L). In addition, with comparable arterial pH levels, the arterial PCO<sub>2</sub> was higher during bicarbonate-CRRT, suggesting less ventilatory requirement to achieve the same arterial pH. Mean values for BUN, creatinine, and phosphorus were not different, while total calcium and magnesium were maintained within normal limits using both types of dialysate. Sodium and glucose were significantly closer to normal with the bicarbonate dialysate. Figure 3 shows the evolution of the acid base status during the first 3 days with each type of dialysate in the 13-patient subgroup.

No complications resulting from the use of the bicarbonate-based dialysate were observed. No spike in temperature following therapy initiation, no related sepsis, and no evidence of solute precipitation before use or at bedside were noted. Hypothermic episodes occurred in several cases and were attributed in part to the extracorporeal circuit; rewarming procedures, such as blankets, heating lamp, or dialysate warming, were only occasionally used. Sixteen patients (32%) were discharged alive from the ICU. The other 34 patients died after a mean of  $30.2 \pm 24.1$  days of hospitalization, leading to a mortality rate of

68%. Of the 16 survivors, 11 required intermittent hemodialysis, at least temporarily, while the other five were free of any dialytic support at discharge from the ICU. The 37 patients treated exclusively with bicarbonate-CRRT and the 13 patients treated with lactate and bicarbonate dialysates had similar mortality rates (61.5% v 64.9%;  $P = NS$ ).

A cost evaluation revealed that a 12- to 15-L bag of the bicarbonate solution costs \$13.68, including all the material and the technicians' working time. Thus, the price of the bicarbonate dialysate is between \$0.91 and \$1.14 per liter. The cost of a 5-L bag of Dianeal 1.5% ranges between \$10 and \$20 dollars, a price of \$2 to \$4 per liter.

## DISCUSSION

During CRRT, there is a bicarbonate loss consequent to diffusive and convective fluxes that must be replaced. It has been estimated that, assuming a relatively stable blood level, a patient could lose nearly 750 mEq of bicarbonate per day with CAVHD.<sup>16</sup> The loss of bicarbonate is expected to be even greater when high ultrafiltration rates are reached. When lactate dialysate is used, the lost bicarbonate is in part regenerated from the absorbed lactate, which, when metabolized, consumes an equivalent number of hydrogen ions and restores the alkali reserve.<sup>17</sup> If the endogenous capacity to metabolize lactate is altered, as in liver failure, this bicarbonate loss could potentially lead to an important decrease in serum bicarbonate level. On the other hand, critically ill patients frequently present high lactic acid levels, usually from overproduction due to poor peripheral perfusion, with an associated metabolic acidosis. While sodium bicarbonate is frequently given to improve the acid base balance of these patients, it has not been demonstrated to change their morbidity or mortality rates.<sup>18-20</sup>

However, one pertinent question that arises is the potential detrimental effect of a significant net administration of lactate anions through CRRT to patients who already may have high lactic acid levels and an altered endogenous metabolizing capacity. In our 22 patients for whom lactic acid was monitored within 24 hours of CRRT initiation, the mean lactic acid level was over 7 mEq/L; thus, many of these patients presented with hyperlactatemia, defined by a level

higher than 5 mEq/L.<sup>18</sup> Dalal et al have shown in chronic hemodialysis patients that although L-lactate high-efficiency hemodialysis was hemodynamically well tolerated, it was associated with hypoxemia and a delayed correction of pH and plasma  $\text{HCO}_3$  concentrations.<sup>21</sup> Davenport et al investigated the effect of an exogenous lactate load in patients with chronic renal failure, ARF, and both acute liver plus renal failure treated by intermittent hemofiltration.<sup>22</sup> All patients developed hyperlactatemia, which was more severe in the liver failure cases. In addition, during treatment, serum lactate levels increased from 1.0 to 4.3 mEq/L, while bicarbonate increased only from 19.3 to 21.3 mEq/L in patients with ARF. The increase in bicarbonate was smaller for ARF cases than for chronic renal failure cases, suggesting that ARF may be accompanied by a relative intolerance to lactate anions.

In an effort to control the acid base status of ARF patients treated by CRRT with a more physiological buffer, and concerned about the possible detrimental effects of a lactate load given during these CRRT when using lactate-based dialysate, we prepared a bicarbonate solution that was a replication of the dialysate used for chronic intermittent hemodialysis. The procedure is both simple and cost-effective. Although expected at the prevalent concentrations,<sup>23</sup> no precipitation of calcium or magnesium salts has been observed; furthermore, as the calcium and magnesium blood concentrations were well maintained during bicarbonate-CRRT, it can be assumed that no significant changes in the composition of the solution occurred within the time of use since the diffusive balance was not affected. In addition, since the source water has not been generated as "sterile," the resultant dialysate should be considered "clean" but not sterile. While the dialysate has been passed through a filtration process and is devoid of bacterial activity, as demonstrated by the absence of colony counts on cultures, the possible presence of endotoxin has not been eliminated.<sup>15,24</sup> Because this possibility exists, we cannot recommend the use of this solution for anything other than dialysate, as it also applies for CRRT. In our series, no septic episodes related to CRRT have been recorded, with the precaution of maintaining the inflow rate lower than the outflow rate to reduce the risk of backfiltration.<sup>14,15</sup>

Good metabolic control was achieved in the 50 patients treated by bicarbonate-CRRT, with electrolytes, calcium, and magnesium levels and the acid base balance maintained within normal or near normal limits. The comparison of the metabolic parameters for the subgroup of 13 patients treated with lactate and bicarbonate dialysates suggests that the bicarbonate solution may be associated with an improved acid base status and better-maintained sodium and glucose concentrations. One could argue that the improved acid base status obtained under bicarbonate dialysate may be consequent to changes in ventilator parameters, partial recovery of endogenous renal acidifying capacity over time, weight loss with reduced bicarbonate volume of distribution, longer treatment period with bicarbonate than with lactate dialysate, or even the sequence of solutions used for treatment, as the bicarbonate dialysate generally followed the lactate dialysate. A prospective study will be required to completely address these issues. However, among these 13 patients, eight died while they were still on CRRT without any evidence of renal function recovery, and four of the five survivors required intermittent hemodialysis after CRRT cessation, thus indicating no significant improvement in endogenous acidifying capacity. Despite similar arterial pH under both types of dialysate, the arterial  $\text{PCO}_2$  was significantly higher, but normal, under bicarbonate dialysate, as opposed to relatively low with the lactate solution. This most probably indicates a reduced need for respiratory compensation to maintain a normal pH. The elevated  $\text{PCO}_2$  content of bicarbonate solution (when over 35 mEq/L) could have induced an increase in blood  $\text{PCO}_2$ , or the greater transfer of bicarbonate from the dialysate solution to blood could have caused a metabolic alkalosis resulting in a hypocapnia and an associated hypoxemia, as described in continuous hemodialysis patients.<sup>25,26</sup> However, despite an improved correction of the metabolic acidosis, overall there was no evidence of metabolic alkalosis in our patients, and since all were mechanically ventilated, the  $\text{PCO}_2$  and  $\text{PO}_2$  were more a reflection of the ventilator parameter adjustments. Although we cannot demonstrate a difference in lactic acid levels under both types of dialysate, since they were monitored erratically and only in a minority of patients, the lower calculated anion gap while

treated with the bicarbonate dialysate compared with the lactate dialysate suggests an underlying decrease in lactate levels with the bicarbonate solution. A decrease in anion gap was found to correlate with the decrease in lactate level in the only previous study using bicarbonate dialysate in five pediatric patients treated with CAVHD.<sup>12</sup> Finally, the observed similar levels of BUN, creatinine, and phosphorus confirm that patients received a comparable dialysis dose delivery.

The difference in plasma sodium is explained by the higher tonicity of the bicarbonate dialysate compared with the relatively hypotonic lactate solution; the lower blood glucose can result from the more physiological glucose concentration in the bicarbonate solution, although other carbohydrate sources or insulin administration were not systematically considered. A net positive transfer of glucose from the dialysate to the patient has been demonstrated during CAVHD with Dianeal 0.5% and shown to increase in a linear mode with the dialysate flow rate.<sup>27</sup> The glucose load is expected to be even greater with Dianeal 1.5%, which has a nonphysiological glucose concentration of 1,300 mg/dL.

The survival rate of the 50 patients was 32%, confirming that the outcome of ARF occurring with multiple organ failure remains poor. As already reported, ARF cases treated by CRRT are frequently more complicated and unstable than those treated by intermittent modalities, explaining in part the high mortality rates observed.<sup>28,29</sup> The mortality rates were similar among patients treated exclusively with bicarbonate dialysate compared with those treated with both types of dialysate. However, this study was not designed to establish any firm conclusion regarding differences in hemodynamic profile or in outcome in relation to the bicarbonate solution. Further evaluation regarding morbidity/mortality outcome will be needed.

In conclusion, the bicarbonate solution prepared as described is relatively simple, is safe, and may be cost-effective in centers performing many CRRTs. Its use, exclusively as dialysate during CRRT, is free of complications and is associated with a well-maintained metabolic control. The more physiologic bicarbonate-buffered dialysate seems to result in an improved acid base balance. In ARF patients presenting with severe metabolic acidosis and in cases of lactate

intolerance, such as liver failure, it appears theoretically advantageous to use this solution as dialysate for CRRT.

## ACKNOWLEDGMENT

The authors are grateful to the dialysis technicians, Steve J. Cigany, Jr, CHT, Maria Magdinec, CHT, Rocky Mercer, CHT, and Eugene Wright, CHT, for their excellent work and collaboration.

## REFERENCES

1. Mitch WE: Uremia and the control of protein metabolism. *Nephron* 49:89-93, 1988
2. Mitch WE, Jurkovitz C, England BK: Mechanisms that cause protein and amino acid catabolism in uremia. *Am J Kidney Dis* 21:91-95, 1993
3. Maniar S, Laouari D, Dechaux M, Motel V, Yvert JP, Mathian B, Kleinknecht C: In vivo unaltered muscle protein synthesis in experimental chronic metabolic acidosis. *Kidney Int* 46:1705-1712, 1994
4. De Marchi S, Cecchin E: Bone-buffering and acidosis in end-stage renal disease. *Semin Dial* 4:148-151, 1991
5. Yudkin J, Cohen RD, Slack B: The hemodynamic effects of metabolic acidosis in the rat. *Clin Sci Mol Med* 50:177-184, 1976
6. Marsiglia JC, Cingolani HE, Gonzales NC: Relevance of beta receptor blockade to the negative inotropic effect induced by metabolic acidosis. *Cardiovasc Res* 7:336-343, 1973
7. Veech RL: The untoward effects of the anions of dialysis fluid. *Kidney Int* 34:587-597, 1988
8. Leunissen KML, Hoortje SJ, Fiers HA, Dekkers WT, Mulder AW: Acetate versus bicarbonate hemodialysis in critically-ill patients. *Nephron* 42:146-151, 1986
9. Zucchelli P, Santoro A: Correction of acid-base balance by dialysis. *Kidney Int* 43:S179-S183, 1993 (suppl 41)
10. Bland LA: Microbiological and endotoxin assays of hemodialysis fluids. *Adv Renal Replace Ther* 2:70-79, 1995
11. Veech RL, Fowler RC: Cerebral dysfunction and respiratory alkalosis during peritoneal dialysis with D-lactate containing dialysis fluids. *Am J Med* 82:572-573, 1986
12. Jenkins RD, Jackson E, Kuhn R, Funk J: Benefit of bicarbonate dialysis during CAVHD. *ASAIO Trans* 36:M465-466, 1990
13. Bosworth C, Swann S, Paganini EP: Evaluation of the IMED Gemini PC2 volumetric infusion pumps in extracorporeal continuous therapy circuits. *Dial Transplant* 19:26-28, 1990
14. Leypoldt JK, Schmidt B, Gurland HJ: Measurements of backfiltration rates during hemodialysis with highly permeable membranes. *Blood Purif* 9:74-84, 1991
15. Klinkmann H, Ebbighausen H, Uhlenbusch I, Vienken J: High-flux dialysis, dialysate quality and backtransport. *Contrib Nephrol* 103:89-97, 1993
16. Siegler MH, Teehan BP: Solute transport in continuous hemodialysis: A new treatment for acute renal failure. *Kidney Int* 32:562-571, 1987
17. Madias NE: Lactic acidosis. *Kidney Int* 28:252-274, 1986

18. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, and the DCA-Lactic Acidosis Study Group: Natural history and course of acquired lactic acidosis in adults. *Am J Med* 97:47-54, 1994
19. Cooper DJ, Walley KR, Wiggs BR, Russell JA: Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. *Ann Intern Med* 112:492-498, 1990
20. Stacpoole PW: Lactic acidosis: The case against bicarbonate therapy. *Ann Intern Med* 105:276-279, 1986
21. Dalal S, Yu AW, Gupta DK, Kar PM, Ing TS, Daugirdas JT: L-lactate high-efficiency hemodialysis: Hemodynamics, blood gas changes, potassium/phosphorus, and symptoms. *Kidney Int* 38:896-903, 1990
22. Davenport A, Will E, Davison AM: The effect of lactate-buffered solutions on the acid-base status of patients with renal failure. *Nephrol Dial Transplant* 4:800-812, 1989
23. Van Stone JC: Hemodialysis apparatus, in Daugirdas JT, Ing TS (eds): *Handbook of Dialysis* (ed 2). Boston, MA, Little, Brown, 1994, pp 30-52
24. Pereira BJG, Snodgrass BR, Hogan PJ, King AJ: Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. *Kidney Int* 47:603-610, 1995
25. Ward RA, Wathen RL, Williams TE, Harding GB: Hemodialysate composition and intradialytic metabolic, acid-base and potassium changes. *Kidney Int* 32:129-135, 1987
26. Gennari FJ, Rimmer JM: Acid-base disorders in end-stage renal disease: Parts 1 and 2. *Semin Dial* 3:81-85, 161-165, 1990
27. Bonnardeaux A, Pichette V, Ouimet D, Geadah D, Habel F, Cardinal J: Solute clearances with high dialysate flow rates and glucose absorption from the dialysate in continuous arteriovenous hemodialysis. *Am J Kidney Dis* 19:31-38, 1992
28. Cosenino F, Chaff C, Piedmonte M: Risk factors influencing survival in ICU acute renal failure. *Nephrol Dial Transplant* 9:179-182, 1994 (suppl 4)
29. Mehta RL: Therapeutic alternatives to renal replacement for critically ill patients in acute renal failure. *Semin Nephrol* 14:64-82, 1994